Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.59 |
| ▸ | BTK | Q06187 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14769227 | 0.95 | CNR2 (0.57) | CNR2BTKMAPTMEN1ALDH1A1 | |
| SCHEMBL14769135 | 0.89 | CNR2 (0.53) | CNR2BTKMAPTMEN1ALDH1A1 | |
| SCHEMBL21110443 | 0.88 | BTK (0.69) | CNR2BTKMAPTMEN1ALDH1A1 | |
| SCHEMBL12519584 | 0.88 | CNR2 (0.58) | CNR2BTKMAPTMEN1ALDH1A1 | |
| SCHEMBL14771996 | 0.87 | BTK (0.72) | CNR2BTKEGFRITK | |
| SCHEMBL14772002 | 0.86 | POLB (0.53) | CNR2BTKMAPTPOLBSLC2A1 | |
| SCHEMBL14771995 | 0.86 | CNR2 (0.61) | CNR2BTKMAPTMEN1ALDH1A1 | |
| SCHEMBL14772001 | 0.85 | BTK (0.44) | CNR2BTKMAPTMEN1ALDH1A1 | |
| SCHEMBL12519750 | 0.83 | BTK (0.77) | CNR2BTKMAPTMEN1ALDH1A1 | |
| SCHEMBL14769212 | 0.83 | CNR2 (0.57) | CNR2BTKMAPTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710222-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | CNR2 238/4885BTK 594/4885MAPT 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.